Cramer: Promising data from coronavirus drug trial ‘beginning of the end of the true nightmare’

Investing News

Jim Cramer

Scott Mlyn | CNBC

CNBC’s Jim Cramer said Wednesday that positive news from Gilead Sciences about a potential treatment for the coronavirus marked a turning point in the fight against Covid-19.

“What I regard this as is the beginning of the end of the true nightmare, which is that it’s a death sentence,” Cramer said on “Squawk Box.”

U.S. stocks soared on Wednesday after Gilead indicated it was seeing positive, preliminary signs about the effectiveness of its antiviral remdesivir in treating coronavirus patients.

Cramer has been hopeful about remdesivir as a possible treatment.

Last week, the “Mad Money” host said, he believes that scientists testing treatments for the coronavirus will succeed in getting patients “out of the hospital faster” and reducing “death sentence” concerns.

On Thursday, Cramer said at the time, “I do feel better about what Gilead is doing.”

Articles You May Like

Snowflake’s stock flies higher as software company’s outlook impresses
Gary Gensler says he was ‘proud to serve’ as SEC chair, defends his approach to crypto regulation
‘I’m 38 and completely broke’: I earn $50,000 a year. What professional degree will guarantee me six figures?
Autonomous Vehicles: Why 2025 Will Usher in the Self-Driving Car
Stock-market investors cheered end of election uncertainty. Policy uncertainty remains.